论文部分内容阅读
目的 :探讨辛伐他汀对高脂血症患者血清总载脂蛋白 E(apo E)水平的影响。方法 :40例高脂血症患者每晚顿服辛伐他汀 10 m g 4周 ,比较服药前后血清甘油三酯 (TG)、胆固醇 (TC)、低密度脂蛋白胆固醇 (L DL - C)、高密度脂蛋白胆固醇 (HDL- C)、apo A1 、apo B、apo E及脂蛋白 (a)〔L p(a)〕水平的变化。结果 :用药后血清 TC及 TG分别下降 2 1.3%及 9.2 % (P <0 .0 0 1,<0 .0 5 ) ,L DL- C下降 2 4.7% (P <0 .0 1) ,apo B及 apo E分别下降 13.8%及34.7% (P <0 .0 5 ,<0 .0 0 1) ,apo A1 增加 7.5 % (P <0 .0 5 )。apo E下降幅值分别与其自身基础值和 TG及 L DL- C基础值呈正相关 (P <0 .0 1,<0 .0 1,<0 .0 5 )。 HDL- C呈增高趋势 ,L p(a)改变无统计学差异。结论 :辛伐他汀能导致血清 apo E水平显著下降其可能参与了抗动脉粥样硬化过程
Objective: To investigate the effect of simvastatin on serum total apolipoprotein E (apo E) in patients with hyperlipidemia. Methods: Forty patients with hyperlipidemia were treated with simvastatin 10 mg every night for 4 weeks. The levels of triglyceride (TG), cholesterol (TC), low density lipoprotein cholesterol (L DL - C) (HDL-C), apo A1, apo B, apo E, and lipoprotein (a) [Lp (a)] were measured. Results: After treatment, serum TC and TG decreased by 2.3% and 9.2% (P <0.01, <0.05), L and DL-C decreased by 4.7% (P < B and apo E decreased by 13.8% and 34.7% (P <0.05, <0.001), while apo A1 increased by 7.5% (P <0.05). The amplitude of apo E decline was positively correlated with its own baseline and TG and L DL-C basal values (P <0.01, <0.01, <0.05). HDL-C showed an increasing trend, L p (a) no significant difference. CONCLUSIONS: Simvastatin can cause a significant decrease in serum apo E levels that may be involved in anti-atherosclerotic processes